月経困難症治療市場 : 2027年までの予測

出版：Market Research Future（マーケットリサーチフューチャー）　出版年月：2022年03月

Dysmenorrhea Treatment Market—Forecast till 2027

レポート目次　　　　お問合せ・ご注文　　　　価格・納期について

Dysmenorrhea Treatment Market- Forecast till 2027

Market Overview
The global dysmenorrhea treatment market is anticipated to witness a healthy market expansion at a CAGR of 7.9% to surpass USD 6,312.88 million by 2027. It is a commonly found disease in women during their menstrual cycle. The changing life and diet impacted the menstrual cycle among ladies. High work pressure, tension deferred the feminine cycle and furthermore caused variable feminine issues. Besides, the ladies impacted by Covid experienced excruciating periods alongside changes in chemical levels and anomalies in the cycle. Such factors drive the dysmenorrhea treatment market and are projected to produce a nice market development in the anticipated time span.
The global market growth is driven by the growing occurrences of dysmenorrhea among teenage girls and increasing cases of menstrual cramps because of genetic disorders. However, the negative impact on products due to side effects caused by the products is expected to restrain the market growth during the review period. The female populace in creating and immature nations faces feminine issues because of restricted mindfulness about treatment, a cultural tension, and different variables. Worldwide wellbeing associations, for example, WHO screen the feminine wellbeing status of ladies and young ladies internationally.

Market Segmentation
The global dysmenorrhea treatment market has been divided based on type, type of treatment, and end-user.
Based on Product Type the global market has been bifurcated into Primary Dysmenorrhea and Secondary Dysmenorrhea.
By Type of Treatment, the market is classified as Pain Relievers, Hormonal Therapy, Surgery, and Others. The End-User segment is further categorized into Hospitals & Clinics, Research Centres, and Others.

Regional Analysis
The region-specific analysis of the global dysmenorrhea treatment market is spread across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas represented the biggest offer in the dysmenorrhea treatment market and is relied upon to keep ruling the market before very long. A lot of this expected interest for dysmenorrhea treatment can be credited to the expanding number of patients experiencing feminine problems.
The dysmenorrhea treatment market in Europe represented the second-biggest income-producing district internationally. The clinical preliminaries zeroed in on diminishing agony related to dysmenorrhea are relied upon to build the quantity of accessible viable treatment choices during the estimated time frame.
Asia-Pacific is one of the quickest developing dysmenorrhea treatment provincial markets during the survey time frame. The elements essentially answerable for the development of the dysmenorrhea treatment market in the region are the expanding populace and the ascent in the degree of mindfulness about the condition made by the government.
The Middle East and Africa dysmenorrhea treatment market represented the least market share and is relied upon to observe huge development before very long during the figure time frame.
Major Players
The prominent companies operating in the global dysmenorrhea market are Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Focus Consumer Healthcare, LLC (US), Novartis AG (Switzerland), Pfizer, Inc. (US), Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France), and Viatris Inc. (US).
COVID 19 Impacts
We are continuously tracking the impact of COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

目次

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF DYSMENORRHEA AMONG ADOLESCENT GIRLS
4.2.2 INCREASING CASES OF MENSTRUAL CRAMPS DUE TO GENETIC DISORDERS
4.3 RESTRAINTS
4.3.1 CONCERNS PERTAINING TO SIDE EFFECTS
4.3.2 HIGH AVAILABILITY OF ALTERNATIVE PRODUCTS
4.4 OPPORTUNITIES
4.4.1 THE EMERGENCE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR DYSMENORRHEA TREATMENT
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION, MARKETING, & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 IMPACT ON WOMEN’S HEALTH
5.3.2 IMPACT ON TREATMENT
6 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 PRIMARY DYSMENORRHEA
6.3 SECONDARY DYSMENORRHEA
7 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT
7.1 OVERVIEW
7.2 PAIN RELIEVERS
7.3 HORMONAL THERAPY
7.4 SURGERY
7.5 OTHERS
8 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS & CLINICS
8.3 RESEARCH CENTRES
8.4 OTHERS
9 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY REGION
9.1 INTRODUCTION
9.2 AMERICAS
9.2.1 NORTH AMERICA
9.2.1.1 US
9.2.1.2 CANADA
9.2.2 LATIN AMERICA
9.3 EUROPE
9.3.1 WESTERN EUROPE
9.3.1.1 GERMANY
9.3.1.2 FRANCE
9.3.1.3 UK
9.3.1.4 ITALY
9.3.1.5 SPAIN
9.3.1.6 REST OF WESTERN EUROPE
9.3.2 EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 AUSTRALIA
9.4.5 SOUTH KOREA
9.4.6 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST
9.5.2 AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 MERGER/ACQUISITION
10.7 FINANCIAL MATRIX
10.7.1 SALES (USD MILLION), 2020
10.7.2 R&D EXPENDITURE (USD MILLION), 2020
11 COMPANY PROFILES
11.1 NOVARTIS AG
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS/SERVICES OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 PFIZER, INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS/SERVICES OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 RECKITT BENCKISER GROUP PLC.
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS/SERVICES OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 SANOFI S.A.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS/SERVICES OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 VIATRIS INC.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS/SERVICES OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 JOHNSON & JOHNSON SERVICES INC.
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS/SERVICES OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 GLAXOSMITHKLINE PLC
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS/SERVICES OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 F. HOFFMANN-LA ROCHE LTD
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS/SERVICES OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 BAYER AG
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS/SERVICES OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 FOCUS CONSUMER HEALTHCARE, LLC
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS/SERVICES OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.10.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
 
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS USED DURING MENSTRUATION IN THE TREATMENT OF PRIMARY DYSMENORRHEA IN ADOLESCENTS AND YOUNG ADULTS
TABLE 3 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 4 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR PRIMARY DYSMENORRHEA, BY REGION, 2018–2027 (USD MILLION)
TABLE 5 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR SECONDARY DYSMENORRHEA, BY REGION, 2018–2027 (USD MILLION)
TABLE 6 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 7 GLOBAL: DYSMENORRHEA TREATMENT MARKET FOR PAIN RELIEVERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 8 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR HORMONAL THERAPY, BY REGION, 2018–2027 (USD MILLION)
TABLE 9 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR SURGERY, BY REGION, 2018–2027 (USD MILLION)
TABLE 10 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 11 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 12 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2018–2027 (USD MILLION)
TABLE 13 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR RESEARCH CENTRES, BY REGION, 2018–2027 (USD MILLION)
TABLE 14 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 15 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY REGION, 2018–2027 (USD MILLION)
TABLE 16 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 17 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 18 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 19 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 20 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 21 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 23 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 24 US: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 25 US: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 26 US: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 27 CANADA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 28 CANADA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 29 CANADA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 30 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 31 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 32 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 33 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY REGION, 2018–2027 (USD MILLION)
TABLE 34 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 35 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 36 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 37 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 38 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 39 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 40 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 41 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 42 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 43 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 44 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 45 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 46 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 47 UK: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 48 UK: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 49 UK: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 50 ITALY: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 51 ITALY: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 52 ITALY: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 53 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 54 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 55 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 56 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 57 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 58 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 59 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 60 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 61 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 62 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 63 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 64 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 65 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 66 CHINA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 67 CHINA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 68 CHINA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 69 INDIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 70 INDIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 71 INDIA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 72 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 73 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 74 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 75 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 76 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 77 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 78 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 79 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 80 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 81 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 82 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 83 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 84 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 86 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 87 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 88 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 89 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 90 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 91 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 92 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)
TABLE 93 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 94 MAJOR PLAYERS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET
TABLE 95 MOST ACTIVE PLAYER IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET
TABLE 96 MERGER/ACQUISITION
TABLE 97 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
TABLE 98 PFIZER, INC.: PRODUCTS/SERVICES OFFERED
TABLE 99 RECKITT BENCKISER GROUP PLC.: PRODUCTS/SERVICES OFFERED
TABLE 100 RECKITT BENCKISER GROUP PLC.: KEY DEVELOPMENTS
TABLE 101 SANOFI S.A.: PRODUCTS/SERVICES OFFERED
TABLE 102 SANOFI S.A.: KEY DEVELOPMENTS
TABLE 103 VIATRIS INC.: PRODUCTS/SERVICES OFFERED
TABLE 104 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED
TABLE 105 GLAXOSMITH KLINE PLC: PRODUCTS/SERVICES OFFERED
TABLE 106 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
TABLE 107 BAYER AG: PRODUCTS/SERVICES OFFERED
TABLE 108 BAYER AG: KEY DEVELOPMENTS
TABLE 109 FOCUS CONSUMER HEALTHCARE, LLC: PRODUCTS/SERVICES OFFERED
 
LIST OF FIGURES
FIGURE 1 GLOBAL DYSMENORRHEA TREATMENT MARKET STRUCTURE
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 3 MARKET DYNAMICS: GLOBAL DYSMENORRHEA TREATMENT MARKET
FIGURE 4 DRIVERS: IMPACT ANALYSIS
FIGURE 5 RESTRAINTS: IMPACT ANALYSIS
FIGURE 6 VALUE CHAIN ANALYSIS OF THE GLOBAL DYSMENORRHEA TREATMENT MARKET
FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL DYSMENORRHEA TREATMENT MARKET
FIGURE 8 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2020 & 2027 (USD MILLION)
FIGURE 9 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2020 & 2027 (USD MILLION)
FIGURE 10 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2020 & 2027 (USD MILLION)
FIGURE 11 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY REGION 2020 & 2027 (USD MILLION)
FIGURE 12 GLOBAL: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020
FIGURE 13 AMERICAS: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020
FIGURE 14 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020
FIGURE 15 EUROPE: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020
FIGURE 16 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020
FIGURE 17 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020
FIGURE 18 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY, 2020
FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET
FIGURE 21 GLOBAL DYSMENORRHEA TREATMENT MARKET: COMPETITIVE LANDSCAPE
FIGURE 22 SALES (USD MILLION), 2020
FIGURE 23 R&D EXPENDITURE (USD MILLION), 2020
FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 NOVARTIS AG: SWOT ANALYSIS
FIGURE 26 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 PFIZER, INC.: SWOT ANALYSIS
FIGURE 28 RECKITT BENCKISER GROUP PLC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 RECKITT BENCKISER GROUP PLC.: SWOT ANALYSIS
FIGURE 30 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 SANOFI S.A.: SWOT ANALYSIS
FIGURE 32 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 VIATRIS INC.: SWOT ANALYSIS
FIGURE 34 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS
FIGURE 36 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 40 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 BAYER AG: SWOT ANALYSIS
FIGURE 42 FOCUS CONSUMER HEALTHCARE, LLC: SWOT ANALYSIS